An Investigation Into The Impact Of Enteric Coated Of Aspirin In Patients With Newly Diagnosed Ischemic Stroke.
Status:
Completed
Trial end date:
2020-03-04
Target enrollment:
Participant gender:
Summary
Uncertainty remains regarding the impact of enteric-coated (EC) aspirin as it relates to the
reduction of CV risk. We hypothesize that EC formulation based on the previous report may
blunt aspirin response as evidenced by reduced Thromboxane A2 (TXA 2) levels in diabetic
patients.